Amundi Lowers Stock Holdings in Boston Scientific Corporation $BSX

Amundi cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,199,754 shares of the medical equipment provider’s stock after selling 2,108,961 shares during the quarter. Amundi owned approximately 0.69% of Boston Scientific worth $1,057,001,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of BSX. Sound Income Strategies LLC lifted its holdings in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the period. 1248 Management LLC bought a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the first quarter worth about $27,000. Kilter Group LLC purchased a new position in Boston Scientific during the second quarter valued at approximately $30,000. Finally, Princeton Global Asset Management LLC bought a new position in Boston Scientific in the second quarter worth approximately $32,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on BSX shares. UBS Group increased their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Finally, Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and a consensus target price of $123.77.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 143,095 shares of company stock valued at $14,228,950 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.59 on Friday. The business has a fifty day moving average of $99.28 and a 200 day moving average of $102.13. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm has a market capitalization of $144.67 billion, a price-to-earnings ratio of 52.19, a price-to-earnings-growth ratio of 1.99 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.